Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Mounjaro, weight loss
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...
Weight-loss injection Mounjaro, or tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this ...
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the ...
Evening Standard on MSN1d
Celebrities who’ve used Ozempic: Oprah Winfrey, James Corden, and moreWhile talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback